Login to Your Account



Acorda buying Biotie for $363M cash, adding phase III PD compound

By Cormac Sheridan
Staff Writer

Tuesday, January 19, 2016

DUBLIN – Faced with the high cost of completing phase III development for its Parkinson's disease drug, tozadenant (SYN115), Biotie Therapies Oyj opted to fold now and agree to a $363 million cash bid from Acorda Therapeutics Inc., rather than hold out in the hope that its value would rise later on the back of positive data.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription